Determining the significance of the N-MYC-WDR5 interaction in neuroblastoma.
Determining the significance of the N-MYC-WDR5 interaction in neuroblastoma.
批准号:
10290439
负责人:
April M. Weissmiller
金额:
$37.98万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-07-01 至 2024-06-30
关键词:
AcuteAgeAgreementAnchorage-Independent GrowthAreaAutomobile DrivingBindingBiologic CharacteristicBiological AssayBiologyBiomassCell LineCell ProliferationChemicalsChildChromatinClinicCollaborationsCombined Modality TherapyDNA SequenceDataDiagnosisDiseaseDistant MetastasisEventFamilyFamily memberFoundationsGap JunctionsGene ExpressionGene Expression RegulationGenesGeneticGenetic TranscriptionGenomeGenomic approachGoalsHistologicHumanImpairmentInfantInterventionLinkLocationLymphomaMYC Family ProteinMYC geneMaintenanceMalignant Childhood NeoplasmMalignant NeoplasmsMeasuresModelingMusN-myc GeneNamesNeuroblastomaOncogenicOncoproteinsPrimary NeoplasmProtein BiosynthesisPublishingResearch ProposalsResolutionRouteSiteSolidSolid NeoplasmSurfaceSurvival RateTestingTherapeuticTractionTranscription ProcessTranslationsWorkangiogenesisbasec-myc Genescancer therapychromatin immunoprecipitationcombatdesigndisorder riskgene synthesisgenetic approachgenome-widehigh riskin vivomembermigrationmouse modelmutantneuroblastoma cellnew therapeutic targetnext generation sequencingprogramsrecruitrisk stratificationsmall moleculesmall molecule inhibitortranscription factortranscriptomicstumortumorigenesis
中文摘要
项目总结/文摘
英文摘要
PROJECT SUMMARY/ABSTRACT
Neuroblastoma (NB) is the most common extracranial solid tumor found in infants, with almost all cases
being diagnosed by the age of five. The most severe cases of neuroblastoma are linked to amplification of
the N-MYC oncogene, which occurs in ~20% of all NB. N-MYC amplification is associated with ~50%
overall survival despite aggressive multimodal therapies, highlighting the need for new targeted therapies to
combat this pediatric cancer. N-MYC, like any MYC protein, must be able to recognize and bind chromatin
in order to activate its oncogenic potential. This project is built on the premise that an essential co-factor for
MYC proteins called WDR5 acts to recruit N-MYC to chromatin at genes that work to maintain
neuroblastoma function, and that targeting the N-MYC-WDR5 interaction can serve as a focal point for anti-
N-MYC based therapies. Support for this hypothesis comes from published data showing that WDR5 is a
conserved regulator of protein synthesis genes across multiple cellular contexts where WDR5 binds and
regulates these loci through its so-called “WIN”-site. In addition, the MYC family member, c-MYC, requires
WDR5 to bind genes associated with biomass accumulation and translation, and the c-MYC-WDR5
interaction is essential for tumor maintenance in lymphoma mouse models. In an N-MYC amplified NB cell
line, preliminary data reveal that targeting the WIN-site of WDR5 using small molecule inhibitors results in a
genome-wide decrease in WDR5 binding, with a subsequent loss of N-MYC binding at specific N-MYC-
WDR5 co-bound genes. And, importantly, disrupting the N-MYC-WDR5 interaction using genetic mutants
impairs the ability of N-MYC to drive anchorage-independent growth, providing evidence that there are
essential tumor functions tied to N-MYC that require interaction with WDR5. Together these data provide a
solid foundation for the notion that N-MYC requires WDR5 to bind and regulate N-MYC-WDR5 co-bound
genes that are important for driving N-MYC specific activities. The goal of this project is to interrogate the N-
MYC-WDR5 interaction in N-MYC amplified neuroblastoma cell lines and determine the influence that
WDR5 has on N-MYC driven transcriptional processes and neuroblastoma function using genetic and
chemical perturbations. Specific Aim 1 will employ genetic and genomic approaches to identify the genes
that are bound by N-MYC and WDR5, and determine at which genes the recruitment of N-MYC is
dependent on the N-MYC-WDR5 interaction. Specific Aim 2 will combine high-resolution transcriptomic
analyses with cellular and in vivo functional assays to challenge the significance of the N-MYC-WDR5
interaction. At the completion of these studies we will have identified the precise genes in which N-MYC
binding and transcription is regulated by the N-MYC-WDR5 interaction, and have directly challenged the
significance of the N-MYC-WDR5 interactions on multiple facets of NB tumorigenesis.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.3390/jcm13010274
发表时间:
2024-01-03
期刊:
JOURNAL OF CLINICAL MEDICINE
影响因子:
3.9
作者:
[Weissmiller, April M., Fesik, Stephen W., Tansey, William P.]
通讯作者:
Tansey, William P.
Exposing the role of MYC in small cell carcinoma of the ovary hypercalcemic type
-
批准号:10728702
-
项目类别:
-
资助金额:$6.57万
-
财政年份:2023
-
负责人:April M. Weissmiller
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: